Amy Marshall

1.3k total citations
7 papers, 65 citations indexed

About

Amy Marshall is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Amy Marshall has authored 7 papers receiving a total of 65 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 2 papers in Pulmonary and Respiratory Medicine and 1 paper in Molecular Biology. Recurrent topics in Amy Marshall's work include CAR-T cell therapy research (5 papers), Virus-based gene therapy research (1 paper) and Cancer Genomics and Diagnostics (1 paper). Amy Marshall is often cited by papers focused on CAR-T cell therapy research (5 papers), Virus-based gene therapy research (1 paper) and Cancer Genomics and Diagnostics (1 paper). Amy Marshall collaborates with scholars based in United States. Amy Marshall's co-authors include Carl H. June, Michael D. Farwell, Vivek Narayan, Karen Dengel, Christina Coughlin, Priti Lal, Joan Gilmore, Lester Lledo, Whitney L. Gladney and Simon F. Lacey and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Neuro-Oncology.

In The Last Decade

Amy Marshall

6 papers receiving 65 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amy Marshall United States	5	53	22	22	19	12	7	65
Alexander M. Leipold Germany	4	38 0.7×	14 0.6×	10 0.5×	13 0.7×	8 0.7×	7	63
Ouiam Bakkacha United States	3	51 1.0×	18 0.8×	13 0.6×	13 0.7×	11 0.9×	5	57
Catia Fonseca United States	3	55 1.0×	34 1.5×	19 0.9×	58 3.1×	4 0.3×	3	103
Viola Katharina Vetter Switzerland	3	58 1.1×	18 0.8×	12 0.5×	59 3.1×	6 0.5×	8	92
A. Winge-Main Norway	4	35 0.7×	30 1.4×	31 1.4×	16 0.8×	5 0.4×	7	72
Waseem Cheema United States	3	81 1.5×	24 1.1×	29 1.3×	45 2.4×	25 2.1×	6	112
Orenthial J. Fulbright United States	4	83 1.6×	19 0.9×	21 1.0×	55 2.9×	10 0.8×	7	98
Andrea Breitkreuz Germany	4	50 0.9×	40 1.8×	9 0.4×	53 2.8×	8 0.7×	5	96
Barchuk As Russia	5	43 0.8×	23 1.0×	54 2.5×	12 0.6×	5 0.4×	24	90

Countries citing papers authored by Amy Marshall

Since Specialization

Citations

This map shows the geographic impact of Amy Marshall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Marshall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Marshall more than expected).

Fields of papers citing papers by Amy Marshall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Marshall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Marshall. The network helps show where Amy Marshall may publish in the future.

Co-authorship network of co-authors of Amy Marshall

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Marshall. A scholar is included among the top collaborators of Amy Marshall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Marshall. Amy Marshall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

Svoboda, Jakub, Daniel J. Landsburg, Sunita D. Nasta, et al.. (2024). Safety and efficacy of armored huCART19-IL18 in patients with relapsed/refractory lymphomas that progressed after anti-CD19 CAR T cells.. Journal of Clinical Oncology. 42(16_suppl). 7004–7004. 11 indexed citations

Logun, Meghan, Stephen Bagley, Daniel Zhang, et al.. (2023). CTIM-40. EARLY RADIOGRAPHIC RESPONSE AND ENGRAFTMENT OF PHASE I FIRST-IN-HUMAN BICISTRONIC CAR T CELLS CORRELATE WITH REAL-TIME AUTOLOGOUS GBM ORGANOID CYTOLYSIS. Neuro-Oncology. 25(Supplement_5). v72–v72. 1 indexed citations

Tanyi, János L., Mark H. O’Hara, Elizabeth O. Hexner, et al.. (2023). 671 Phase 1 trial of human chimeric antigen receptor modified T cells (huCART-meso) administered in combination with oncolytic virus VCN-01 in patients with pancreatic and ovarian cancer. SHILAP Revista de lepidopterología. A760–A761.

Narayan, Vivek, Whitney L. Gladney, Gabriela Plesa, et al.. (2020). A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 38(6_suppl). TPS269–TPS269. 20 indexed citations

Narayan, Vivek, Whitney L. Gladney, Gabriela Plesa, et al.. (2019). A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 37(7_suppl). TPS347–TPS347. 25 indexed citations

O’Keefe, Stephen J., Daniel F. Heitjan, Amy Marshall, et al.. (2014). Interim results of a phase 1b/2a study evaluating the nano pharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 32(4_suppl). 412–412. 4 indexed citations

Stevenson, James, Hedy L. Kindler, Anjana Ranganathan, et al.. (2012). Phase II trial of anti-transforming growth factor-beta (TGFß) monoclonal antibody GC1008 in relapsed malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology. 30(15_suppl). 7077–7077. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact